FA
ONCT

FCG Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

FCG Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-7
Closed -$6K – 139
2016
Q2 		$6K Sell
7
-4
-36% -$3.74K ﹤0.01% 132
2016
Q1 		$8K Sell
11
-6
-35% -$5.2K ﹤0.01% 95
2015
Q4 		$17K Hold
17
– – 0.01% 83
2015
Q3 		$18K Hold
17
– – 0.01% 79
2015
Q2 		$35K Buy
+17
New +$24.2K 0.03% 78

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FCG Advisors's ONCT Position: Q3 2016 in Review

FCG Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2016, closing a stake of 7 shares — an estimated $6K sold.

FCG Advisors first reported a position in ONCT in Q2 2015 and held it in 5 quarters. The position peaked at $35K in Q2 2015. 41 funds tracked by Wall St. Rank hold ONCT as of Q3 2016.

  • FCG Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • FCG Advisors sold 7 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $6K.
  • FCG Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2015 and held it in 5 quarters.
  • FCG Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $35K in Q2 2015.
  • 41 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2016.

Based on FCG Advisors's 13F filing for Q3 2016, filed 15 Nov 2016.